Conditions: HIV Infection
Keywords: treatment experienced
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 352
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with HIV.

Detailed description:

Arms:
arm 1: Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir ) arm 2: Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)

Interventions: intervention 1: MK0518 (raltegravir) intervention 2: Comparator: KALETRA™ (lopinavir (+) ritonavir ) intervention 3: Comparator: placebo intervention 4: Comparator: placebo
Intervention descriptions: intervention 1: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment intervention 2: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment. intervention 3: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment intervention 4: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.

Protocol document: